Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Boehringer Ingelheim
Moodys
McKesson

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

GLATOPA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Glatopa, and what generic alternatives are available?

Glatopa is a drug marketed by Sandoz Inc and is included in two NDAs.

The generic ingredient in GLATOPA is glatiramer acetate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Glatopa

A generic version of GLATOPA was approved as glatiramer acetate by MYLAN on October 3rd, 2017.

  Start Trial

Drug patent expirations by year for GLATOPA
Drug Prices for GLATOPA

See drug prices for GLATOPA

Recent Clinical Trials for GLATOPA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Kansas Medical CenterPhase 1

See all GLATOPA clinical trials

Synonyms for GLATOPA
147245-92-9
5M691HL4BO
AB0110033
AC-28732
AM84438
C9H11NO3.C6H14N2O2.
COP-1
Copaxone
Copolymer 1
Copolymer-1
DTXSID30163637
FHEAIOHRHQGZPC-KIWGSFCNSA-N
FT-0686728
Glatiramer acetate
Glatiramer acetate [USAN:BAN]
Glatiramer acetate [USAN]
Glatirameracetat
L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1)
L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt)
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)
LS-186971
LS-71889
Protiramer
Q418274
TV 5010
UNII-5M691HL4BO
Y0429

US Patents and Regulatory Information for GLATOPA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc GLATOPA glatiramer acetate INJECTABLE;SUBCUTANEOUS 090218-001 Apr 16, 2015 AP RX No No   Start Trial   Start Trial   Start Trial
Sandoz Inc GLATOPA glatiramer acetate INJECTABLE;SUBCUTANEOUS 206921-001 Feb 12, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Boehringer Ingelheim
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.